ERBB2 and breast cancer: The three CDK4/6 inhibiting agents showed more favorable outcomes when combined with the mainstay hormonal therapy for HR+/HER-2 breast cancer patients in terms of prolonged survival compared to their comparator endocrine therapy alone (20–27).